Therapix Biosciences Ltd.
Latest News & Stories on Therapix Biosciences Ltd. (NASDAQ:TRPX) (TASE:TRPX)
Therapix Biosciences Ltd. (NASDAQ:TRPX) (TASE:TRPX) is a specialty clinical-stage pharmaceutical company specializing in the development of cannabinoid-based drugs. With this focus, Therapix has initiated two internal drug development programs based on repurposing a U.S. Food and Drug Administration approved synthetic cannabinoid (dronabinol). These two developments include: Joint Pharma developing THX-TS01 targeted to the treatment of Tourette Syndrome, and BrainBright Pharma developing THX-ULD01 targeted to the high value and under-served market of mild cognitive impairments.